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Abstract
Background: Despite increasing international interest, there is a lack of evidence 
about the most efficient, effective and acceptable ways to implement patient and pub-
lic involvement (PPI) in clinical trials.
Objective: To identify the priorities of UK PPI stakeholders for methodological re-
search to help resolve uncertainties about PPI in clinical trials.
Design: A modified Delphi process including a two round online survey and a stake-
holder consensus meeting.
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1  | INTRODUCTION
Growing awareness of the importance of patient centeredness in 
research1,2 has influenced the establishment of Patient- Centred 
Outcomes Research Institute in the United States, the National 
Institute for Health Research (NIHR) INVOLVE organization in the 
United Kingdom (UK) and similar bodies elsewhere. These organiza-
tions have been at the vanguard of international efforts to involve 
patients as research partners, alongside researchers, to set research 
agendas, design studies and decide what outcomes should be mea-
sured.3,4 The emphasis on patient centeredness in research stems 
from a belief that involving patients in decisions about how studies are 
designed and conducted improves research, making it more relevant 
to end users3,5-7 and reducing waste.8,9 Patient involvement is also 
believed important for moral reasons, based on the principle that the 
people whose lives are most affected by research should have a say. 
In the UK, patient involvement is known as patient and public involve-
ment (PPI).5,10 In clinical trials, PPI tends to involve a small number of 
patients or members of the public (known as PPI contributors).11 Some 
PPI contributors will have direct personal experience of the condition 
being investigated, whilst others bring general experience of being a 
patient or service user. A key consideration is that PPI contributors 
are in a position to offer a distinctive perspective to researchers or 
clinicians. Many UK funders require researchers seeking funding to 
provide evidence of how PPI will inform their studies.12-14
Despite the emphasis on PPI in the UK and internationally, there 
are uncertainties about how best to implement it,15 about the pur-
pose of PPI and whether it actually does improve research.10,12,15,16 
Concerns have been raised about tokenism and resourcing in PPI, 
about the difficulty of ensuring diversity and avoiding professionaliza-
tion among PPI contributors,10,17,18 complexities with researchers and 
patients sharing power,19 and inadequacies in training and support for 
both PPI contributors and researchers.20 Problems with the concep-
tualization and meaningful assessment and measurement of PPI have 
also been identified.21
Each of these concerns points to different priorities for method-
ological research on PPI. Reviews of PPI in research and other contexts 
identify many topics for future research.4,21-24 Although not all reviews 
focus specifically on clinical trials, trials are regarded as particularly 
likely to benefit from PPI20,25 by helping to address the many meth-
odological issues that arise within trials.5 Most reviews of PPI echo 
similar concerns to those identified in the above paragraph, pointing 
to the need for: agreed tools for measuring PPI and its impact across 
the different phases of research,15,24,26,27 for investigations of how best 
to support PPI6,23,28 and for optimal models of implementing PPI.29,30 
However, many of these topics have been identified by PPI researchers 
and it is unclear whether these priorities are shared by the wider com-
munity of trialists and PPI stakeholders. Given the diversity of stake-
holders involved in PPI, there is considerable potential for divergence 
in the prioritization of topics to investigate, and therefore for dilution 
of research efforts in investigating how to improve PPI in research.
In the METHODs for Patient and Public Involvement In Clinical 
TriALs (METHODICAL study), we conducted a modified Delphi pro-
cess to identify the priorities of a broad range of PPI stakeholders for 
methodological research to resolve uncertainties about PPI in clinical 
trials, as well as to help improve to the design of future PPI research 
and avoid unnecessary duplication of research effort.
2  | MATERIALS AND METHODS
Delphis are used in health and social science research as a means of in-
volving participants with relevant experience, via a multistaged study, 
to achieve consensus on a given topic.16,31,32 This involves conducting 
Participants: In total, 237 people registered of whom 219 (92%) completed the first 
round. One hundred and eighty- seven of 219 (85%) completed the second; 25 stake-
holders attended the consensus meeting.
Results: Round 1 of the survey comprised 36 topics; 42 topics were considered in 
round 2 and at the consensus meeting. Approximately 96% of meeting participants 
rated the top three topics as equally important. These were as follows: developing 
strong and productive working relationships between researchers and PPI contribu-
tors; exploring PPI practices in selecting trial outcomes of importance to patients; and 
a systematic review of PPI activity to improve the accessibility and usefulness of trial 
information (eg participant information sheets) for participants.
Conclusions: The prioritized methodological research topics indicate important areas 
of uncertainty about PPI in trials. Addressing these uncertainties will be critical to en-
hancing PPI. Our findings should be used in the planning and funding of PPI in clinical 
trials to help focus research efforts and minimize waste.
K E Y W O R D S
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sequential anonymous surveys to collect, collate and present results 
back to the group. To help achieve consensus, participants can view 
and revise their own responses in the light of group responses.32 The 
process can be modified to include opportunities for feedback or a 
consensus meeting so that participants can discuss their views.33,34 
We designed a modified Delphi, comprising a literature review to 
identify topics for research on PPI, followed by a two round online 
survey and stakeholder consensus meeting.
We established a study team of 17 PPI stakeholders from across 
the UK to oversee the METHODICAL project, including: four PPI 
Coordinators, eight PPI researchers, one PPI planner, two PPI contrib-
utors, one non- lay reviewer and one lay reviewer. Seven members of 
the team had secondary PPI- related roles.
2.1 | Patient involvement
Our study team included three patient partners who were involved 
in all aspects of study design and conduct, including development 
of protocol, pilot topics and accompanying text, survey recruit-
ment, interpretation of study findings and review of this manuscript. 
Approximately half of the consensus meeting places were allocated to 
patients. We will send participants a summary of the study findings. 
The summary will also be placed on the study website and promoted 
through social media platforms used by patients.
2.2 | Recruitment
To help maximize the utility of our findings, we aimed to include all 
key paid and unpaid roles of people who co- ordinate, support and 
contribute to PPI in trials. Individuals were eligible to participate in the 
Delphi process if they had at least 12 months’ experience within a PPI 
role in clinical trials. Study team members did not participate in the 
survey. As definitions of roles in PPI vary, the study team identified 
seven stakeholder groups to inform recruitment, consulting with our 
PPI partners to select terminology to define each group (Table 1). We 
provided this list of stakeholder groups and accompanying definitions 
in recruitment materials. A free text field was included at registration 
so participants could elaborate on their role/s and self- identify their 
role if they felt this was not included in the list. The study team agreed 
that for the feedback of results in round 2 to be meaningful at the 
level of stakeholder group, approximately 10 participants per group 
would be required.
We used snowball sampling to identify stakeholders35 using per-
sonal contacts and Internet searches to develop a database of individ-
uals, organizations and networks under each of the seven stakeholder 
groups. The METHODICAL researcher (AK) sent emails to the iden-
tified organizations, networks and individuals (Table S1) with study 
information. The email included a request to invite potential survey 
participants by distributing the study invitation to their members 
or contacts. AK also placed an advert and link to the survey on the 
“People in Research Forum” (www.peopleinresearch.org).
2.3 | Development and pilot of topics
We used online search engines (eg Google Scholar and OVID 
(MEDLINE), organizational databases (eg INVOLVE library) and 
hand searches of citations within key articles to identify literature 
that systematically evaluated the scope and impact of PPI within 
health research15,20,24 to develop a list of potential methodological 
research topics for round 1 of the Delphi. This was supplemented 
by reviewing recent publications assessing PPI specifically within 
clinical trials.22,23,27,36 For each topic, we developed accompanying 
descriptive text to help explain these. The study team, including 
PPI partners reviewed the list of topics and accompanying de-
scriptions to ensure they were distinct and clearly communicated 
challenges associated with PPI in clinical trials. Methodological re-
search in this context was described to participants in study infor-
mation materials as: “methods, practices and procedures of PPI in 
clinical trials.” We piloted the list of topics with a small group of 
lay (n=2) and non- lay (n=3) PPI stakeholders to check clarity and 
understanding and then refined the list of topics and descriptive 
text (Figure 1).
2.4 | Online survey
The online Delphi was conducted between November 2015 and 
March 2016. Round 1 was open for approximately 5 weeks and round 
2 for 4.5 weeks.
TABLE  1 Stakeholder groups for the Delphi process
Stakeholder Group Definition and examples
PPI Contributors Patient representatives, research partners in clinical trials
Lay Reviewers Members of the public sitting on clinical trial funding boards or Research Ethics Committees (RECs)
PPI Coordinators Roles within a clinical trial unit (CTU) or research network to coordinate PPI activity and PPI contributors and research 
partners in trials
PPI Advisors Roles offering advice on how to design and deliver PPI activity within trials. This predominantly includes member of the 
National Institute for Health Research (NIHR) Research Design Service (RDS)
PPI Planners Chief Investigators, trial managers and other researchers/staff who plan or oversee PPI in individual trials
PPI Researchers People who conduct research into PPI in clinical trials and authors of PPI guidance documents
Non- lay Reviewers Professional members of clinical trial funding boards or Research Ethics Committees (RECs)
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In round 1, stakeholders registered for the study by indicating their 
name, email address, which of the seven stakeholder groups they had 
the most experience in, years of PPI experience, consent to participate, 
interest in attending the consensus meeting and interest in receiving 
a copy of the published findings. We assigned each registered user 
a unique identifier to ensure anonymity and enable linking of scores 
between rounds. Participants then scored the importance of each of 
research topic using a scale of 1- 9, with scores 1- 3 being not critical 
or low importance, 4- 6 important but not critical and 7- 9 of critical 
importance.37 Selecting a score of 10 indicated an abstention from 
scoring an individual topic. Participants were also invited to suggest 
additional topics to be added to round 2. Participants who registered 
but did not start the survey, or partially completed round 1 questions, 
were excluded from the analysis and not invited for round 2. The study 
team reviewed additional topics suggested by participants in round 1 
for inclusion in round 2.
In round 2, we showed participants bar charts summarizing the 
distribution of the percentage of scores 1- 9 for each topic from 
each stakeholder group. We then invited participants to revise or 
keep their own score from the previous round. The email invita-
tion for round 2 indicated that responses received within 10 or 
17 days would be entered into prize draws for a £50 voucher or a 
F IGURE  1 Overview of the Delphi process
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£30 voucher, respectively. AK sent email reminders periodically to 
non- responders.
2.5 | Consensus meeting
We allocated thirty places to equal numbers of lay and non- lay stake-
holders with broad representation across the seven stakeholder 
groups. The METHODICAL study team were invited to attend and 
participate in the consensus meeting. Three study team members 
helped to facilitate the meeting and did not take part. Ten other study 
team members registered to attend as participating stakeholders and 
were allocated either lay or non- lay places based on their primary PPI 
roles. We invited survey participants at random within their stake-
holder group. Only survey participants who completed both rounds of 
the survey and who registered their interest in attending the consen-
sus meeting were eligible to attend.
AK emailed each registered attendee a copy of the agenda and their 
scores from round 2 one week before the meeting. PW, a member of 
the METHODICAL team, facilitated the meeting due to her previous 
experience in this role. PW had no vested interests in the ranking of 
research priorities, although like all survey participants, she is involved 
in the design and delivery of clinical trials. Team members KW and AK 
began the meeting with a short- study overview. KW presented the re-
sults from round 2 sequentially and in the same order as presented in 
the online survey. Each topic and accompanying description were pre-
sented together with bar charts showing how each stakeholder group 
had scored each topic. We provided attendees with paper copies of 
their individual scores and the level of consensus achieved within stake-
holder groups during round 2 (Table S4). PW began by asking attendees 
if any clarification of the topic was required. Comments and discussion 
were then encouraged before PW asked attendees to consider whether 
or not the topic should be prioritized for future research. Where more 
than 70% of round 2 participants in any one stakeholder group had 
indicated a topic was of high importance (scored it 7- 9), we invited at-
tendees to raise opposing arguments. A similar approach was followed 
for those topics where less than 50% of round 2 participants in any one 
group had indicated a topic to be of less importance (scored it 1- 3), with 
views requested if a participant felt strongly that a topic should be con-
sidered important. PW encouraged a fuller discussion where the online 
survey results indicated mixed views on a topic. Following discussion 
of each topic an anonymous vote was undertaken using a hand held 
voting device (Turning Point software, version 5, Turning Technologies, 
youngstown, Ohio, USA). Meeting attendees could abstain from voting 
for an individual topic by selecting a score of 10. This process was re-
peated until all topics were discussed and voted on.
AK circulated a written report to meeting attendees seven weeks 
after the meeting, which included notes from meeting discussions and 
any changes made to the topic description text.
2.6 | Statistical analysis
We pre- defined consensus as 70% or more participants scoring from 7 
to 9 and less than 15% participants scoring from 1 to 3 on a particular 
topic.38,39 All statistical analysis was performed in R version 3.2 (R 
Foundation for Statistical Computing , Vienna, Austria. www. R-project.
org/). We ranked final research topics from the METHODICAL con-
sensus meeting according to the percentage of participants scoring a 
research topic as critically important (scores 7- 9) and then by ascend-
ing order of the percentage of scores 1- 3.
3  | RESULTS
3.1 | Online survey
Of the 237 people who registered for the survey, 219 (92%) com-
pleted round 1. Twelve individuals registered but did not start the 
survey and six provided partial responses (Figure 1). All 18 individu-
als were excluded from the analysis. Of the 219 who completed 
round 1, 187 (85%) completed round 2 and were included in the 
analysis. Of the remaining 32, one withdrew from round 2 of the 
survey, two died, two partially completed round 2, and 27 did not 
complete any part. Completion rates by stakeholder group for round 
1 and 2 are shown in Table 2. Round 1 of the survey comprised 36 
methodological research topics (Table S2). The study team reviewed 
81 additional research topics suggested by survey participants. Of 
these, we agreed that 46 suggestions were within the scope of ex-
isting topics, although we added additional examples to seven ex-
isting topics or descriptors to improve their clarity. Twenty- eight 
suggestions contributed to the development of six new topics which 
were added to round 2. The remaining seven suggestions related 
to trial participants not PPI and were therefore considered to be 
out of scope. However, these led to the inclusion of a new topic 
aimed at exploring the definition of PPI and people’s understanding 
of it. Round 2 of the survey comprised of 42 methodological re-
search topics, including the six new topics created from participant 
suggestions.
At the end of round 2, we reviewed results against the definition 
of consensus agreed at the beginning of the study. At the end of round 
2, there was no consensus across all stakeholder groups as to which 
research topics were of critical importance. Only three topics achieved 
consensus across six of the seven groups (Table S4).
3.2 | Consensus meeting
Of the 30 people registered, 25 attended and were eligible to vote 
(Table 2). Seventeen were survey participants and eight were mem-
bers of the METHODICAL study team. Twelve (48%) attendees were 
lay, and 13 (52%) were non- lay. Although no attendees identified PPI 
advisor as the stakeholder group that they most identified with, at 
least two had PPI advisor roles; all stakeholder groups were, there-
fore, represented at the meeting.
All 42 topics were discussed, and voting was undertaken on all ex-
cept two, topics 38 and 39. Following discussion attendees concluded 
that topic 38 (methods to measure PPI impact) should be subsumed 
within topic 37 (core outcomes to evaluate PPI), while topic 39 (char-
acteristics of PPI which lead to a successful trial) was considered to be 
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too broad. We made changes to three topic titles and nine descriptive 
texts after group discussion in order to clarify the topic before voting 
(Table S2).
Table S3 provides the final ranked list of all research topics. Sixteen 
topics achieved consensus with greater than 70% of participants scor-
ing them 7- 9 and less than 15% scoring them 1- 3. As shown in Table 3, 
the top 10 prioritized research topics were varied, covering PPI pro-
cesses, resources, practices and relationships between stakeholder 
groups. Three topics shared joint “first place” with 96% of meeting 
attendees rating each as critically important: developing strong and 
productive working relationship between researchers and PPI con-
tributors; PPI practices in selecting trial outcomes of importance to 
patients; and a systematic review of PPI activity in improving the ac-
cessibility and usefulness of trial information (eg leaflets and informa-
tion sheets) for clinical trial participants.
As discussed previously, an additional topic, regarding the defini-
tion of PPI and people’s understanding of it, was added to round 2. 
Attendees gave low ratings for this topic, commenting that improved 
communication about the definition of PPI was needed within the tri-
als community rather than more research on this definition. Of the six 
topics suggested by survey participants, only one (Topic 13: Exploring 
the role of PPI in the early stages of testing of new treatments [eg 
Phase 1 and Phase 2 trials]) reached consensus among meeting 
 attendees (Table S3).
4  | DISCUSSION
Through a consensus building process, we have identified priority 
topics for methodological research to inform PPI in clinical trials. The 
prioritized research topics were varied, covering PPI processes, re-
sources, practices and relationships between stakeholder groups. The 
number and range of topics considered by more than 70% of meet-
ing participants to be critically important indicates the high level of 
uncertainty and lack of evidence to inform PPI in clinical trials.2,4,23,27 
Meeting attendees were virtually unanimous about the most im-
portant PPI research priorities, with the top six achieving over 92% 
consensus.
Several of the top 10 prioritized research topics address concepts 
that are fundamental to PPI in clinical trials, such as productive work-
ing relationships, resources and how to adapt PPI models to avoid a 
one size fits all approach.30 Previous studies of PPI in clinical trials 
have particularly highlighted the importance of productive working re-
lationships in creating the sort of environment to enable contributors 
to make a difference to research,27,40,41 whilst Barber et al., recom-
mended considering PPI as a dynamic partnership rather than a pro-
cedural activity.17 During the consensus meeting many stakeholders 
shared examples of poor relationships between PPI contributors and 
researchers, also reflecting the high priority placed on the develop-
ment of strong and productive partnerships between researchers and 
PPI contributors.
Whilst online resources such as INVOLVE provide costing tools 
for planning PPI, publications are poor at reporting the true costs.42 
Topic 9 (resources needed for PPI activity), highlights uncertainties 
around PPI costs and points to concerns regarding the adequacy of 
funding to meet these costs. Research is, therefore, needed to help 
identify what level of resource is required for the implementation of 
PPI to ensure plans for such involvement are realistic and adequately 
supported. Whilst work is being undertaken to develop frameworks 
and guidelines to guide PPI practice in research,43-45 PPI plans and 
activities often vary according to context.23 Two of the top ten prior-
itized topics (Topics 4 and 2) point to concerns about current models 
of PPI,29,30 highlighting the need for research to explore adaptations 
of PPI to the needs of particular trials, as well as methods to capture 
wider patient and public perspectives. For example, concerns were 
raised about current models of PPI being tokenistic, due to often small 
numbers (one or two) PPI contributors working on each trial.10,17,18 
Research is needed to evaluate the effectiveness of different methods 
TABLE  2 Stakeholder representation within the survey and at the meeting
Stakeholder group
No. 
Registered
No. who completed 
round 1 (% of 
registereda)
No. who completed 
round 2 (% of  
round 1)
No. who accepted the 
meeting invitation (% of 
round 2 completers)
No. of meeting 
attendees (% of 
those invited)
Lay reviewers 51 48 (94) 39 (81) 7 (18) 6 (86)
PPI contributors 37 36 (97) 27 (75) 8 (30) 6 (75)
Total Lay 88 84 (95) 66 (79) 15 (23) 12 (80)
Non- lay reviewers 40 38 (95) 33 (87) 3 (9) 3 (100)
PPI Planners 53 47 (89) 39 (83) 4 (10) 4 (100)
PPI advisors 13 12 (92) 12 (100) 1 (8) 0b (0)
PPI coordinators 26 25 (96) 25 (100) 4 (16) 4 (100)
PPI researchers 17 13 (76) 12 (92) 3 (25) 2 (67)
Total Non- lay 149 135 (91) 121 (90) 15 (12) 13 (87)
Total 237 219 (92) 187 (85) 30 (16) 25 (83)
aFor example, the percentage of Lay reviewers who registered and completed round 1 (94%) is the number who completed (n=48) divided by the number 
registered (n=51).
bAt least two people with secondary roles of PPI advisor were present at the consensus meeting.
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to increase diversity and capture wider patient or public perspectives 
on clinical trial designs, such as online surveys and social media.
Some of the top ten topics focus on the impact of PPI and particu-
larly the need to review PPI in specific trial processes, such as: the de-
velopment of trial information for patients; recruitment and retention of 
patients; choice and measurement of outcomes; and the dissemination 
of results. Two of these (Topic 28, strategies to recruit and retain pa-
tients, and Topic 29, the selection of trial outcomes) align with existing 
methodological research agendas for clinical trials.38 Conceptually, PPI 
should have a substantial role in addressing these issues. However, our 
results demonstrate that further work is needed to map and formally 
evaluate current PPI practices to help make these more relevant to tri-
als,3,5-7 and help to reduce research waste by targeting resources more 
effectively.8,9 For example, it is common to involve patients in develop-
ing information materials for prospective trial participants,43 yet it is un-
clear whether or how this input increases participation rates or improves 
patient experience of research.20 A systematic review of PPI activity in 
the development of information materials for prospective trial partici-
pants (Topic 31) may provide evidence of the impact of such work, as 
well as inform future PPI in this important aspect of trial development.
During the consensus meeting some prioritized topics were re-
vised to define a research method to be used to explore that partic-
ular topic, such as Topic 31: “A systematic review of PPI activity in 
improving accessibility and usefulness of trial leaflets and information 
sheets for clinical trial participants’”, whilst others, such as Topic 20 
“Developing strong and productive working relationships between 
researchers and PPI contributors” are more wide ranging and relate 
to challenges in PPI. Such wider topics may contain multiple compo-
nents, and further consideration will be needed to develop these top-
ics into formal research questions and to identify the most appropriate 
 research methods for addressing these questions.32
4.1 | Strengths and limitations
Our study had several strengths. The METHODICAL team included 
representation of all stakeholder groups including lay and non- lay 
members, who oversaw all stages of the project, including the recruit-
ment strategy. The survey sample size was also relatively large com-
pared to other Delphi studies, and attrition was low. Comparison of 
round 1 mean scores between those who did and did not complete 
round 2 indicate that our study was not affected by attrition bias 
(Figure S1).
We took several steps to help ensure that all stakeholder groups 
were represented at every stage of the Delphi and that all groups and 
individuals felt able to contribute freely. We sampled stakeholders 
purposively for the survey stage. For the consensus meeting a random 
selection of participants within groups ensured balance and fairness in 
the allocation places for lay and non- lay stakeholders across all seven 
of stakeholder groups.
High and low priority topics identified in our study are cited 
in international literature on public and patient involvement in re-
search.46-48 However, further research is required to explore the level 
of priority given to these topics in international settings.
The study also had some limitations. As the potential sample was 
large and diverse we were unable to fully define the sampling frame 
and used snowball sampling to try to make sure all stakeholder groups 
were included in the sample. As a result, our study was subject to self- 
selection bias among those who registered for the study. To minimize 
the burden of survey participation, we chose not to collect social or 
demographic information, such as ethnicity or socio- economic sta-
tus; therefore, the diversity of participants and the potential impact 
of socio demographic characteristics upon the prioritization process 
cannot be evaluated.
Some study team members participated in the discussion and vot-
ing within the consensus meeting, which meant that a subset of at-
tendees was not independent from the project. We reasoned that they 
would bring valuable experience and expertise to the discussion49 and 
therefore included them in the meeting. To promote transparency, at 
the beginning of the meeting all attendees introduced themselves and 
stated whether they took part in the survey, or whether they were 
a member of the study team. Care was taken in the facilitation of 
the meeting to ensure that all attendees had an equal opportunity 
to contribute to discussions. To help attendees feel free to vote as 
they wished during the meeting, voting was anonymous. Fifteen of 25 
(60%) of attendees completed an optional feedback survey, of whom 
14 of 15 (93%) were satisfied with how the meeting was facilitated 
and felt it produced a fair and independent outcome. However, as we 
did not track individual votes during the meeting, we are unable to 
present consensus meeting voting data by stakeholder group, or as-
sess how individual scores differed from the online survey.
Delphis are dependent upon the participants having time to com-
mit to the process to completion.50 To reduce the potential burden on 
participants and minimize attrition bias, we pre- specified a two round, 
rather than a three or four round survey.33,51,52 While consensus was 
not achieved in the two round survey, it was achieved at the meeting, 
which highlights the value of face- to- face discussion and collective 
deliberation in reaching consensus.
Rather than beginning with an open question about possible topics 
and inviting suggestions from participants, the list of topics presented 
in round 1 was derived from the existing literature.53 However, we also 
invited participants to suggest additional topics in round 1. Despite 
a large number of suggested topics, relatively few new topics were 
suggested. Indeed, the majority of topics put forward by participants 
were already encompassed by existing topics. This perhaps indicates 
that our approach of presenting a list of topics in round 1 was an ap-
propriate way of conducting a methodological research priority setting 
exercise in a context where not all stakeholders would be familiar with 
the concept of methodological research and might struggle to identify 
priorities without some examples as prompts.
5  | CONCLUSIONS
In conclusion, the prioritized methodological research topics identi-
fied by the Delphi process highlight key uncertainties about PPI in 
trials. Addressing these uncertainties will be critical to enhancing 
     |  9KEARNEY Et Al.
PPI. Our findings should be used by those involved in planning and 
 funding of PPI in clinical trials to help focus research efforts and 
 minimize waste.
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